Molecular Partners AG (MOLN)
NASDAQ: MOLN · Real-Time Price · USD
4.500
+0.180 (4.17%)
Mar 11, 2025, 4:00 PM EST - Market closed
Molecular Partners AG Revenue
In the year 2024, Molecular Partners AG had annual revenue of 4.97M CHF, down -29.38%.
Revenue (ttm)
4.97M CHF
Revenue Growth
-29.38%
P/S Ratio
29.09
Revenue / Employee
29,672 CHF
Employees
168
Market Cap
159.53M USD
Revenue Chart
* This company reports financials in CHF.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 4.97M | -2.07M | -29.38% |
Dec 31, 2023 | 7.04M | -182.56M | -96.29% |
Dec 31, 2022 | 189.60M | 179.85M | 1,843.82% |
Dec 31, 2021 | 9.75M | 410.00K | 4.39% |
Dec 31, 2020 | 9.34M | -11.04M | -54.16% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
MOLN News
- 4 days ago - Molecular Partners AG (MOLN) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 5 days ago - Molecular Partners Reports Highlights from Q4 2024 and Key Financials for Full Year 2024 - GlobeNewsWire
- 12 days ago - Molecular Partners Announces Participation at Upcoming Investor Conferences and 2024 Financial Results Conference Call - GlobeNewsWire
- 7 weeks ago - Molecular Partners: Leveraging Its Biologics Platform Into Early Clinical Programs - Seeking Alpha
- 2 months ago - Molecular Partners Outlines Clinical Expansion Plans and Strengthens Radiopharma Strategic Focus for 2025 at 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 2 months ago - Molecular Partners and Orano Med expand partnership to develop Targeted Alpha Radio-Therapies for cancer - GlobeNewsWire
- 3 months ago - Molecular Partners to Present at JP Morgan Healthcare Conference and Baader Helvea Swiss Equities Conference in January - GlobeNewsWire
- 3 months ago - Molecular Partners Presents Clinical Data Supporting its Ongoing MP0533 Study and Preclinical Data on Next-Gen Conditioning Agent MP0621 at ASH 2024 - GlobeNewsWire